<DOC>
	<DOCNO>NCT02847286</DOCNO>
	<brief_summary>A Study assess drug-drug interaction potential , Dapivirine Vaginal Ring-004 , contain 25 MG Dapivirine .</brief_summary>
	<brief_title>To Assess Drug-drug Interaction Potential Between Dapivirine Vaginal Ring-004 , Containing 25 mg Dapivirine , Clotrimazole 10 mg/g ( 1 % )</brief_title>
	<detailed_description>AN OPEN-LABEL , RANDOMISED TRIAL , WITH A THREE-PERIOD CROSSOVER PART IN HEALTHY HIV-NEGATIVE WOMEN TO ASSESS THE DRUG-DRUG INTERACTION POTENTIAL BETWEEN DAPIVIRINE VAGINAL RING-004 , CONTAINING 25 MG OF DAPIVIRINE , AND CLOTRIMAZOLE 10 mg/g ( 1 % ) ADMINISTERED AS A VAGINAL CREAM , WITH A FOLLOW-ON PERIOD TO ASSESS THE EFFECT OF MULTIPLE RING REMOVALS AND RE-INSERTIONS DURING THE 28-DAY PERIOD OF THE DAPIVIRINE VAGINAL RING-004 USE ON THE SYSTEMIC AND LOCAL EXPOSURE AND RESIDUAL AMOUNT OF DAPIVIRINE IN USED RINGS</detailed_description>
	<criteria>Participants must meet follow criterion eligible enrol trial : 1 . Women 18 â‰¤ 45 year age give write informed consent 2 . Available visit consent follow procedure schedule trial 3 . Healthy , base medical history , vital sign , physical examination , urinalysis ( dipstick microscopy ) , laboratory evaluation genital infection ( bacterial vaginosis , gonorrhoea , chlamydia trichomonas ) , laboratory evaluation haematology chemistry 4 . HIVnegative determine HIV test time screen 5 . On stable form contraception , define : A stable oral contraceptive regimen least 2 month prior enrolment , OR Transdermal contraceptive patch least 3 month prior enrolment , OR Longacting progestin least 6 month prior enrolment , OR An intrauterine device ( IUD ) insert ( vaginal gynaecological complaint associate use ) least 3 month prior enrolment , OR Have undergone surgical sterilisation least 3 month prior enrolment , AND willing use oral contraceptive necessary delay menstruation vaginal sampling period 6 . Upon pelvic examination time enrolment , cervix vagina appear normal determined Investigator/Physician Asymptomatic genital infection time enrolment ( woman diagnose treatable STI , either clinically laboratory test time screening , must complete treatment prior enrolment ) 8 . Willing refrain use topical vaginal medication , vaginal product object , include female condom , tampon , cotton wool , rag , diaphragm , cervical cap ( vaginal barrier method ) , douche , lubricant , vibrators/dildos , dry agent 14 day prior enrolment duration trial 9 . Documentation abnormality cervical cytology , include grossly bloody smear , within 90 day prior screen 10 . Willing refrain participation research trial duration trial 11 . Willing provide adequate locator information trial retention purpose reachable per local standard procedure , e.g . home visit telephone , via family close neighbour contact ( confidentiality maintain ) 12 . Willing agree abstain total 2 day ( 48 hour ) prior trial visit : Penilevaginal intercourse Oral contact genitalia 13 . Hepatitis B C negative time screen Participants follow criterion NOT eligible enrol trial : 1 . Currently pregnant last pregnancy outcome within 3 month prior screen 2 . Currently breastfeed 3 . Currently within 2 month participation clinical research trial involve investigational market product prior screen 4 . Untreated symptomatic urogenital infection , e.g . urinary tract STIs , gynaecological condition vaginal itching , pain , discharge within 14 day prior enrolment 5 . History significant urogenital uterine prolapse , undiagnosed vaginal bleeding , urethral obstruction , incontinence , urge incontinence anatomical variation allow placement retention ring 6 . Current vulvar vaginal symptoms/abnormalities could influence trial result 7 . Cervical cytology screen require cryotherapy , biopsy , treatment ( infection ) , evaluation 8 . Symptomatic genital herpes simplex virus ( HSV ) infection history genital herpetic infection 9 . Any Grade 2 , 3 4 haematology , biochemistry urinalysis laboratory abnormality baseline ( screen ) accord Division Acquired Immunodeficiency Syndrome ( DAIDS ) Table Grading Severity Adult Pediatric Adverse Events ; Addendum 1 Female Genital Grading Table Use Microbicide Studies 10 . Unexplained , abnormal bleed per vagina follow vaginal intercourse , gynaecologic surgery within 90 day prior enrolment 11 . Any history anaphylaxis severe allergy result angioedema ; history sensitivity/allergy latex silicone 12 . Any serious acute , chronic progressive disease ( e.g . know history neoplasm , cancer , diabetes , epilepsy , cardiac disease , autoimmune disease , HIV , Acquired Immunodeficiency Syndrome [ AIDS ] , blood dyscrasia ) , sign cardiac disease , renal failure , severe malnutrition 13 . Have undergone hysterectomy 14 . Any condition ( ) , opinion Investigator , might interfere adherence trial requirement evaluation trial objective . Participants follow criterion NOT eligible Treatment F : 15 . Using hormonal intrauterine device .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>